E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy

Haematologica. 2017 Aug;102(8):e297-e299. doi: 10.3324/haematol.2017.168740. Epub 2017 May 11.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Fusion Proteins, bcr-abl / genetics
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Male
  • Middle Aged
  • Protein Kinase Inhibitors / therapeutic use*
  • Protein-Tyrosine Kinases
  • RNA, Neoplasm*
  • Remission Induction
  • Withholding Treatment*

Substances

  • Protein Kinase Inhibitors
  • RNA, Neoplasm
  • Protein-Tyrosine Kinases
  • Fusion Proteins, bcr-abl